RSS-Feed abonnieren

DOI: 10.1055/s-0043-1771264
Deceptive Presentation of Low-Grade Lymphoma with Grade 3 Marrow Fibrosis and Aplasia: Diagnostic and Clinical Considerations
Autoren
Funding None.
Abstract
Bone marrow fibrosis with lymphoproliferative disorders is rare with the exception of hairy cell leukemia and nodular sclerosis Hodgkin's lymphoma. We report the case of a 63-year-old gentleman with indolent B-cell lymphoma presenting with myelofibrosis and aplasia. He was evaluated for pancytopenia with no organomegaly or lymphadenopathy. Bone marrow aspiration was a dry tap and biopsy revealed a hypocellular marrow with a cellularity of 10 to 20% with absent megakaryocytes and grade 2 to 3 reticulin fibrosis. Myeloproliferative neoplasms were ruled out based on morphology and absence of myeloid mutations on next-generation sequencing. Further sections revealed interstitial infiltrates of lymphoid cells with round, clumped chromatin and inconspicuous nucleoli, which on immunohistochemistry (IHC) were positive for CD20 and BCL2, and negative for CD5, CD10, BCL6, annexin A1, cyclin D1, and TdT. The final diagnosis was thus confirmed as CD5-negative low-grade B-cell lymphoma and he was initiated on therapy with a combination of Bendamustine and Rituximab. He had resolution of symptoms and cytopenia after six cycles of the same. Presence of significant myelofibrosis on the background of a hypocellular marrow can mimic several subtypes of myeloproliferative neoplasms or myelodysplastic syndromes, providing a diagnostic challenge. IHC is essential in determining the exact subtype to decide further therapy. Based on literature search, only a handful of patients with this presentation have been described and this case will be a valuable addition to the same.
Keywords
lymphoma - histopathology - fibrosis - diagnosis - pathology - biopsy - cancer - immunohistochemistryAuthor's Contributions
S.S., R.S. and J.S. wrote the manuscript. P.P. evaluated the morphological images, reviewed the manuscript, and approved the final version.
Patient's Consent
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given her consent for images and other clinical information to be reported in the journal. The patient understands that name and initials will not be published and due efforts will be made to conceal the identity, but anonymity cannot be guaranteed.
Publikationsverlauf
Artikel online veröffentlicht:
07. August 2023
© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Lee WI, Lee JH, Kim IS, Lee KN, Kim SH. Bone marrow involvement by non-Hodgkin's lymphoma. J Korean Med Sci 1994; 9 (05) 402-408
- 2 Ishibashi M, Hisano S, Kimura N. et al. Clinical evaluation of bone marrow fibrosis in non-Hodgkin's lymphomas. Rinsho Ketsueki 1992; 33 (03) 297-302
- 3 Duarte ÍX, Domeny-Duarte P, Wludarski SCL, Natkunam Y, Bacchi CE. Follicular lymphoma in young adults: a clinicopathological and molecular study of 200 patients. Mod Pathol 2013; 26 (09) 1183-1196
- 4 Etienne A, Gruson B, Chatelain D. et al. Myelofibrosis-associated lymphoproliferative disease: retrospective study of 16 cases and literature review. Adv Hematol 2009; 2009: 179847
- 5 Langabeer SE. Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics. JAK-STAT 2016; 5 (2-4): e1248011
- 6 Wang H-Y, Zu Y. Diagnostic algorithm of common mature B-cell lymphomas by immunohistochemistry. Arch Pathol Lab Med 2017; 141 (09) 1236-1246
- 7 Falini B, Tiacci E, Liso A. et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004; 363 (9424) 1869-1870
- 8 Miao Y, Lin P, Saksena A. et al. CD5-negative mantle cell lymphoma: clinicopathologic correlations and outcome in 58 patients. Am J Surg Pathol 2019; 43 (08) 1052-1060
- 9 Matsunaga T, Takemoto N, Miyajima N. et al. Splenic marginal zone lymphoma presenting as myelofibrosis associated with bone marrow involvement of lymphoma cells which secrete a large amount of TGF-beta. Ann Hematol 2004; 83 (05) 322-325
- 10 Tsutsui M, Yasuda H, Ota Y, Komatsu N. Splenic marginal zone lymphoma with prominent myelofibrosis mimicking triple-negative primary myelofibrosis. Case Rep Oncol 2019; 12 (03) 834-837
- 11 Nakayama S, Yokote T, Hiraoka N. et al. Role of mast cells in fibrosis of classical Hodgkin lymphoma. Int J Immunopathol Pharmacol 2016; 29 (04) 603-611
- 12 Tataroglu C, Sarioglu S, Kargi A, Özkal S, Aydin O. Fibrosis in Hodgkin and non-Hodgkin lymphomas. Pathol Res Pract 2007; 203 (10) 725-730
- 13 Rumi E, Zibellini S, Boveri E. et al. Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. Am J Hematol 2019; 94 (07) E185-E188
- 14 Iannitto E, Bellei M, Amorim S. et al. Efficacy of Bendamustine and Rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. Br J Haematol 2018; 183 (05) 755-765
